ArticleTranslational gastroenterology and hepatology2018
Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, randomised, double-blind, parallel group, clinical study.
Article in Translational gastroenterology and hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.United European gastroenterology journal · 2019Trial
- Beyond Weight Loss: Gut Microenvironment Modulation to Enhance Cardiometabolic Outcomes and Long-Term Adherence During Incretin-Based Therapy.Journal of clinical medicine · 2026Review
- Drug Survival of Drugs Recommended for Irritable Bowel Syndrome: A Retrospective Observational Study.Neurogastroenterology and motility · 2025Observational
- A streamlined workflow for a fast and cost-effective count of tyndallized probiotics using flow cytometry.Frontiers in microbiology · 2024Article
- Accidental Intravenous Administration of Simethicone in a 4-Year-Old Patient: A Case Report.Acta medica Lituanic · 2024Article
- Article
- Heat-KilledJournal of microbiology and biotechnology · 2022Article
- Best Practices for Probiotic Research in Athletic and Physically Active Populations: Guidance for Future Randomized Controlled Trials.Frontiers in nutrition · 2022Review
- Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome.Therapeutic advances in gastroenterology · 2021Article
- Heat-inactivated Lactobacillus plantarum nF1 promotes intestinal health in Loperamide-induced constipation rats.PloS one · 2021Article
- Impact of Heat-KilledNutrients · 2020Article
- An Infant Milk Formula Supplemented with Heat-Treated ProbioticFoods (Basel, Switzerland) · 2020Article
- Constipation and the Quality of Life in Conservatively Treated Chronic Kidney Disease Patients: A Cross-sectional Study.International journal of medical sciences · 2020Article
- International Society of Sports Nutrition Position Stand: Probiotics.Journal of the International Society of Sports Nutrition · 2019Review
- Health Benefits of Heat-Killed (Tyndallized) Probiotics: An Overview.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBloating is a common symptom reported by around 16% to 31% of the general population. Functional bloating is diagnosed in patients with recurrent symptoms of bloating who do not meet the diagnostic criteria of irritable bowel syndrome or other functional gastrointestinal disorders.
methodsThis double-blind, multicentre, randomised study compared the safety and efficacy of APT036 (xyloglucan plus tyndallized
resultsBoth APT036 (n=54) and simethicone (n=54) were well tolerated by study subjects; no adverse effects were reported with either treatment. Compared with simethicone, APT036 significantly reduced abdominal distension (P=0.008) and flatulence (P=0.010) from baseline to Day 30. The baseline hydrogen breath test confirmed the presence of small intestinal bacterial overgrowth (SIBO) in all subjects. At Day 20, mean hydrogen gas elevation was below the threshold for a diagnosis of SIBO (<12 ppm above basal on glucose administration) in both study arms.
conclusionsBoth APT036 and simethicone had good safety profiles but APT036 was superior to simethicone in relieving symptoms of functional bloating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.